Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Proposes NIP Inclusion of 15-Valent Pneumococcal Vaccine for Kids
November 10, 2023
- Industry Prods Careful Debate on Creating Separate Rules for Leqembi Re-Pricing
November 9, 2023
- MHLW Cautions against Hoarding Oseltamivir Dry Syrup amid Tight Stocks
November 9, 2023
- Chugai’s Fujihara, Alfresa’s Arakawa to Represent Industry at Chuikyo
November 9, 2023
- Accumulate Knowledge to Prevent Dementia, a “National Issue”: PM Advisor
November 8, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
- LDP Lawmakers Air Concerns over MOF Push for Negative Fee Revision
November 8, 2023
- Abecma Clears Japan Panel Review for 3rd Line MM Use
November 7, 2023
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Japan PM Advisor Pushes Rethink of LLP Coverage to Reward Innovation, Pricing Debate without Taboos
November 6, 2023
- Japan OKs New Economic Package; Startup, Pharma Promotion Embraced
November 6, 2023
- FPMAJ Renews Call for Premium for Drugs Launched in Japan without Delay: LDP Confab
November 6, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- Japan PM Pins Hope for Leadership of Kamoshita as Drug Policy Advisor
November 2, 2023
- MHLW to Consider Investigation on OTC Drug Abuse: Minister
November 2, 2023
- Organization to Push Drug Discovery Is One Option: Health Minister
November 1, 2023
- Basic Dementia Law Set to Take Effect on January 1: MHLW
November 1, 2023
- Japan Economic Package to Call for Boosting Innovation for Next-Gen Biologics
November 1, 2023
- Cases of Unintentional Xocova Use in Pregnant Women Total 32: MHLW
October 31, 2023
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…